New combo therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT04827862
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tests a combination of the immunotherapy drug pembrolizumab and low-dose radiation in people with non-Hodgkin lymphoma that has come back or not responded to treatment. Participants receive radiation to one or more tumor sites and then continue pembrolizumab until the disease gets worse or side effects become too much. The goal is to see if this approach can shrink tumors and control the disease longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abamson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.